<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00928226</url>
  </required_header>
  <id_info>
    <org_study_id>BRN0010</org_study_id>
    <secondary_id>SU-04272009-2418</secondary_id>
    <secondary_id>15107</secondary_id>
    <nct_id>NCT00928226</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases</brief_title>
  <official_title>A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the optimal treatment dose for large brain metastases. Brain metastases are
      conventionally treated with radiation to the whole brain and/or focal radiation with
      stereotactic radiosurgery. With conventional radiation, control rates (i.e., the ability to
      completely eradicate the tumor) of large brain metastases of size greater 4 cm3 are poor. By
      treating these tumors over 3 treatment sessions, we hope to improve the control rate and
      decrease side effects for patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of SRS given in 3 fractions for brain metastases 4.2 - 14.1 cm3 and 14.2 - 33.5 cm3.</measure>
    <time_frame>60 days (per patient)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the local control rate as assessed on MRI and clinical exam</measure>
    <time_frame>3, 6, 9, and 12 months following treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine short term and long term adverse effects</measure>
    <time_frame>60 days (per patient)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the distant intra-cranial control rate</measure>
    <time_frame>3, 6, 9, and 12 months following treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the patients health related quality of life</measure>
    <time_frame>1, 3, 6, 9, and 12 months following treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the overall survival rate</measure>
    <time_frame>Until death</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Cancer of Brain and Nervous System</condition>
  <condition>Metastatic Malignant Neoplasm to Brain</condition>
  <arm_group>
    <arm_group_label>4.2 - 14.1 cm3 brain metastasis following surgical resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>14.2 - 33.5 cm3 brain metastasis following surgical resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4.2 - 14.1 cm3 unresectable brain metastasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.2-14.1 cm3 unresectable brain metastasis treated with SRS alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14.2 - 33.5 cm3 unresectable brain metastasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14.2 - 33.5 cm3 unresectable brain metastasis treated with SRS alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fractionated Stereotactic Radiosurgery</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>4.2 - 14.1 cm3 brain metastasis following surgical resection</arm_group_label>
    <arm_group_label>14.2 - 33.5 cm3 brain metastasis following surgical resection</arm_group_label>
    <arm_group_label>4.2 - 14.1 cm3 unresectable brain metastasis</arm_group_label>
    <arm_group_label>14.2 - 33.5 cm3 unresectable brain metastasis</arm_group_label>
    <other_name>Cyberknife surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Linear accelerator</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>4.2 - 14.1 cm3 brain metastasis following surgical resection</arm_group_label>
    <arm_group_label>14.2 - 33.5 cm3 brain metastasis following surgical resection</arm_group_label>
    <arm_group_label>4.2 - 14.1 cm3 unresectable brain metastasis</arm_group_label>
    <arm_group_label>14.2 - 33.5 cm3 unresectable brain metastasis</arm_group_label>
    <other_name>linear particle accelerator</other_name>
    <other_name>linac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients age 18 years and older with pathologically proven solid tumor malignancy
             and 1 to 4 brain metastases, one of which is 4.2 - 33.5 cm^3.

          -  Systemic therapy:  Prior cytoxic systemic therapy must be completed &gt;= 5 days prior
             to radiosurgery.  No concurrent cytoxic systemic therapy along with SRS.  Cytoxic
             systemic therapy to start &gt;= 5 days after the completion of SRS.

          -  Prior surgery or SRS is allowed as long as the target metastatic lesion in this study
             has not previously been treated with SRS.

          -  Patient must exhibit the ability to understand and the willingness to sign a written
             informed consent.

          -  Life expectancy of at least 12 weeks.

        Exclusion Criteria:

          -  Patients who have previously been treated with whole brain irradiation.

          -  Patients whose metastatic lesion in question had previously been treated with SRS.

          -  The patient has greater than 4 total brain metastases at the time of initial
             evaluation.

          -  Pediatric patients (age &lt;18), pregnant women, and patients who are unable to give
             informed consent will be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Soltys</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Modlin</last_name>
    <phone>(650) 723-8843</phone>
    <email>lmodlin@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Modlin</last_name>
      <phone>650-723-8843</phone>
      <email>lmodlin@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Clinical Trials Office</last_name>
      <phone>(650) 498-7061</phone>
    </contact_backup>
    <investigator>
      <last_name>Scott Soltys</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John R. Adler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Daniel Chang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Catrice Gibbs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Griffith R. Harsh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>June 23, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
